GMP Capital Inc. (GMP.TO)
TSE:GMPGMP Capital Inc., an independent financial services company, provides various financial products and services to corporate clients, institutional investors, and high-net-worth individuals in Canada, the United States, and internationally. It operates in two segments, Operations Clearing and Wealth Management. The Operations Clearing segment provides carrying broker services, including trade execution, clearing, settlement, custody, and other middle and back-office services to Richardson GMP and Stifel Nicolaus Canada Inc. The Wealth Management segment provides wealth management and investment services. GMP Capital Inc. was founded in 1995 and is headquartered in Toronto, Canada.
Paramount Resources
TSE:POUParamount Resources Ltd. explores for and develops conventional and unconventional petroleum and natural gas reserves and resources in Canada. The company holds interests in the Karr and Wapiti Montney properties covering an area of 109,000 net acres located south of the city of Grande Prairie, Alberta; Kaybob North Duvernay development and natural gas producing properties covering an area of 124,000 net acres located in west-central Alberta; and Willesden Green Duvernay development in central Alberta and shale gas producing properties in the Horn River Basin in northeast British Columbia covering an area of 249,000 net acres. Paramount Resources Ltd. was founded in 1976 and is based in Calgary, Canada.
SQZ Biotechnologies
NYSE:SQZSQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.